Logo image of IOVA

IOVANCE BIOTHERAPEUTICS INC (IOVA) Stock Fundamental Analysis

NASDAQ:IOVA - Nasdaq - US4622601007 - Common Stock - Currency: USD

1.655  -0.1 (-5.97%)

Fundamental Rating

3

Taking everything into account, IOVA scores 3 out of 10 in our fundamental rating. IOVA was compared to 562 industry peers in the Biotechnology industry. The financial health of IOVA is average, but there are quite some concerns on its profitability. While showing a medium growth rate, IOVA is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year IOVA has reported negative net income.
In the past year IOVA has reported a negative cash flow from operations.
IOVA had negative earnings in each of the past 5 years.
In the past 5 years IOVA always reported negative operating cash flow.
IOVA Yearly Net Income VS EBIT VS OCF VS FCFIOVA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100M -200M -300M -400M

1.2 Ratios

The Return On Assets of IOVA (-40.88%) is comparable to the rest of the industry.
The Return On Equity of IOVA (-52.39%) is better than 63.52% of its industry peers.
Industry RankSector Rank
ROA -40.88%
ROE -52.39%
ROIC N/A
ROA(3y)-52.47%
ROA(5y)-47.04%
ROE(3y)-69.19%
ROE(5y)-60.44%
ROIC(3y)N/A
ROIC(5y)N/A
IOVA Yearly ROA, ROE, ROICIOVA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60

1.3 Margins

IOVA has a better Gross Margin (24.43%) than 72.78% of its industry peers.
IOVA does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 24.43%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IOVA Yearly Profit, Operating, Gross MarginsIOVA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10K -20K -30K

More info and screens

4

2. Health

2.1 Basic Checks

IOVA does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, IOVA has more shares outstanding
Compared to 5 years ago, IOVA has more shares outstanding
IOVA has a better debt/assets ratio than last year.
IOVA Yearly Shares OutstandingIOVA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M
IOVA Yearly Total Debt VS Total AssetsIOVA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

IOVA has an Altman-Z score of -2.69. This is a bad value and indicates that IOVA is not financially healthy and even has some risk of bankruptcy.
IOVA has a Altman-Z score (-2.69) which is comparable to the rest of the industry.
IOVA has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
IOVA has a Debt to Equity ratio (0.00) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -2.69
ROIC/WACCN/A
WACC9.99%
IOVA Yearly LT Debt VS Equity VS FCFIOVA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M 600M

2.3 Liquidity

IOVA has a Current Ratio of 3.74. This indicates that IOVA is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of IOVA (3.74) is comparable to the rest of the industry.
IOVA has a Quick Ratio of 3.31. This indicates that IOVA is financially healthy and has no problem in meeting its short term obligations.
IOVA has a Quick ratio of 3.31. This is comparable to the rest of the industry: IOVA outperforms 40.57% of its industry peers.
Industry RankSector Rank
Current Ratio 3.74
Quick Ratio 3.31
IOVA Yearly Current Assets VS Current LiabilitesIOVA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 31.11% over the past year.
Looking at the last year, IOVA shows a very strong growth in Revenue. The Revenue has grown by 13698.99%.
EPS 1Y (TTM)31.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%14.29%
Revenue 1Y (TTM)13698.99%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%6798.46%

3.2 Future

Based on estimates for the next years, IOVA will show a very strong growth in Earnings Per Share. The EPS will grow by 22.21% on average per year.
IOVA is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 55.31% yearly.
EPS Next Y38.43%
EPS Next 2Y32.27%
EPS Next 3Y31.41%
EPS Next 5Y22.21%
Revenue Next Year81.52%
Revenue Next 2Y75.84%
Revenue Next 3Y66.86%
Revenue Next 5Y55.31%

3.3 Evolution

IOVA Yearly Revenue VS EstimatesIOVA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B
IOVA Yearly EPS VS EstimatesIOVA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 -1 -2

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for IOVA. In the last year negative earnings were reported.
Also next year IOVA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IOVA Price Earnings VS Forward Price EarningsIOVA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IOVA Per share dataIOVA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2

4.3 Compensation for Growth

IOVA's earnings are expected to grow with 31.41% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y32.27%
EPS Next 3Y31.41%

More info and screens

0

5. Dividend

5.1 Amount

IOVA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

IOVANCE BIOTHERAPEUTICS INC

NASDAQ:IOVA (5/16/2025, 9:40:10 AM)

1.655

-0.1 (-5.97%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-08 2025-05-08/amc
Earnings (Next)08-06 2025-08-06/amc
Inst Owners82.91%
Inst Owner Change-0.37%
Ins Owners0.26%
Ins Owner Change18.13%
Market Cap552.65M
Analysts82.11
Price Target19.57 (1082.48%)
Short Float %26.08%
Short Ratio5.9
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)6.42%
Min EPS beat(2)4.58%
Max EPS beat(2)8.26%
EPS beat(4)4
Avg EPS beat(4)5.26%
Min EPS beat(4)2.54%
Max EPS beat(4)8.26%
EPS beat(8)7
Avg EPS beat(8)11.99%
EPS beat(12)10
Avg EPS beat(12)9.11%
EPS beat(16)10
Avg EPS beat(16)5.77%
Revenue beat(2)1
Avg Revenue beat(2)3.24%
Min Revenue beat(2)-0.2%
Max Revenue beat(2)6.69%
Revenue beat(4)2
Avg Revenue beat(4)-8.93%
Min Revenue beat(4)-66.23%
Max Revenue beat(4)24.03%
Revenue beat(8)2
Avg Revenue beat(8)-48.03%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-7.18%
PT rev (3m)-19.3%
EPS NQ rev (1m)-0.38%
EPS NQ rev (3m)-1%
EPS NY rev (1m)2.1%
EPS NY rev (3m)2.95%
Revenue NQ rev (1m)-2.11%
Revenue NQ rev (3m)0.72%
Revenue NY rev (1m)0.15%
Revenue NY rev (3m)4.68%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.37
P/FCF N/A
P/OCF N/A
P/B 0.78
P/tB 1.29
EV/EBITDA N/A
EPS(TTM)-1.24
EYN/A
EPS(NY)-0.33
Fwd EYN/A
FCF(TTM)-1.09
FCFYN/A
OCF(TTM)-1.06
OCFYN/A
SpS0.49
BVpS2.13
TBVpS1.28
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -40.88%
ROE -52.39%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 24.43%
FCFM N/A
ROA(3y)-52.47%
ROA(5y)-47.04%
ROE(3y)-69.19%
ROE(5y)-60.44%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.18
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 33.37%
Cap/Sales 6.75%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.74
Quick Ratio 3.31
Altman-Z -2.69
F-Score6
WACC9.99%
ROIC/WACCN/A
Cap/Depr(3y)118.96%
Cap/Depr(5y)1133.86%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)31.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%14.29%
EPS Next Y38.43%
EPS Next 2Y32.27%
EPS Next 3Y31.41%
EPS Next 5Y22.21%
Revenue 1Y (TTM)13698.99%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%6798.46%
Revenue Next Year81.52%
Revenue Next 2Y75.84%
Revenue Next 3Y66.86%
Revenue Next 5Y55.31%
EBIT growth 1Y15.78%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year40.78%
EBIT Next 3Y27.6%
EBIT Next 5YN/A
FCF growth 1Y5.22%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y2.44%
OCF growth 3YN/A
OCF growth 5YN/A